Page 191 of 440: studies 1,901 to 1,910 of 4,392, newest first. Back to the psilocybin overview
DMW - Deutsche Medizinische Wochenschrift July 1, 1959 W. de Borr 1 citation
Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study
Helvetica Chimica Acta 1959 F. Troxler, Frauke Seemann, A. Hofmann 69 citations
Abstract Various modifications were made in the molecular structure of the natural psychotropic substances psilocybin (I) and psilocin (11) to obtain an insight into the relationship between structure and psychotropic action of this group of substances. A description is given of the synthesis and properties of the position isomers of I and II with a phosphoryloxy or hydroxy group in position 5,...
Helvetica Chimica Acta 1959 A. Hofmann, Richard R. Heim, André Brack et al. 225 citations
Abstract The psychotropically active principles of the Mexican hallucinogenic fungus Psilocybe maxicana H EIM have been isolated and obtained in crystalline form. The two new substances, which have been called psilocybin and psilocin , are present in the fruit bodies, the artificially cultivated mycelium and in the sclerotia. The dried mushroom contains 0.2 to 0.4 per cent psilocybin. Psilocin...
American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 14 citations
The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is...
Clinical Neuropharmacology Ramiro Manzano-Nunez, Diego A Gomez, Catalina Toledo-Mendoza et al. 3 citations
This scoping review aimed to synthesize the existing data about psilocybin pharmacokinetics to learn what has been described regarding body disposition and safety when psilocybin was used in controlled research settings. We performed a scoping literature review following the framework proposed by the JBI manual for evidence synthesis. Controlled clinical trials reporting pharmacokinetic data of...
Vidushani Dhanawansa, Devon Stoliker, Leonardo Novelli et al.
Background: Psilocybin is a serotonergic psychedelic that provides a pharmacological tool for examining neural activity associated with altered states of consciousness. Existing studies report reduced power (4-30 Hz) in posterior regions and altered functional connectivity (FC) at rest, but have typically involved small samples and coarse anatomical parcellations. Additionally, perceptual...
Janis Ancans preprint
AbstractBackground. Existential distress and treatment-resistant depression are common and difficult to manage in patients with serious and life-limiting illnesses. Psilocybin-assisted therapy has shown early promise for these conditions, but access outside research settings remains narrow, inconsistent, expensive and often shaped by outdated eligibility rules. These include extremely limited...
Janis Ancans preprint
Legal access to psilocybin almost always requires a medical diagnosis first, usually treatment-resistant depression (TRD) or severe PTSD, as though informed consent alone was not sufficient. This article makes two connected arguments. Extending the autonomy argument already accepted for terminally ill patients, competent adults who understand the potential benefits and risks of a psilocybin...
Carolyn M. L. Crawford, Zach Walsh, W. Francois Louw et al.
Chronic pain is a prevalent and disabling condition, making access to safe and effective pain treatments a public health priority. Early but encouraging results have emerged from research investigating the therapeutic potential of psilocybin for people living with chronic pain (PLCP). This growing line of work urges an understanding of PLCP’s receptivity to this treatment. Aim. The primary aim...
Lena K L Oestreich, Hugh McGovern, Zohaib Nadeem et al. preprint
Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...